BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Elranatamab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Elranatamab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06421675-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06421675)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Outpatient an
 d Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myelo
 ma\nEstimated primary completion: December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/elranatamab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06421675
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06015542-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06015542)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Self-administ
 ration of Subcutaneous Elranatamab in the Patients' Homes.\nEstimated prim
 ary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/elranatamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06015542
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06832865-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06832865)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: ELISA in Rela
 psed/Refractory MM\nEstimated primary completion: 1 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/elranatamab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06832865
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Elranatamab: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Elranatamab\, phase 1/2\, Multiple Myeloma.\nStudy: Study to Ev
 aluate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated prima
 ry completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/elranatamab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04068597
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06988488-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Elranatamab: Phase 1/2 readout est. (NCT06988488)
DESCRIPTION:Elranatamab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Determine the Recommended Dose and Schedule\, and Evaluate the Safety and 
 Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Par
 ticipants With Relapsed and/or Refractory Multiple Myeloma\nEstimated prim
 ary completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/elranatamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06988488
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06183489-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06183489)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Use of Elrana
 tamab in Patients With High-risk Smoldering Multiple Myeloma\nEstimated pr
 imary completion: July 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/elranatamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06183489
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05927571-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Elranatamab: Phase 1 readout est. (NCT05927571)
DESCRIPTION:Elranatamab\, phase 1\, Multiple Myeloma.\nStudy: A Study Evalu
 ating the Safety\, Pharmacokinetics\, and Activity of the Combination of C
 evostamab and Elranatamab in Participants With Relapsed or Refractory Mult
 iple Myeloma (R/R MM)\nEstimated primary completion: 31 July 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/elranatamab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05927571
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05317416-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20270804
DTEND;VALUE=DATE:20270805
SUMMARY:Elranatamab: Phase 3 readout est. (NCT05317416)
DESCRIPTION:Elranatamab\, phase 3\, Multiple Myeloma.\nStudy: Study With El
 ranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple My
 eloma After Transplant\nEstimated primary completion: 4 August 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/elranatamab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05317416
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07788469-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Elranatamab: Phase na readout est. (NCT07788469)
DESCRIPTION:Elranatamab\, phase na.\nStudy: A Study of Elranatamab for Inhi
 bitor Eradication in Patients With Hemophilia A\nEstimated primary complet
 ion: October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/el
 ranatamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07788469
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789522-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20271009
DTEND;VALUE=DATE:20271010
SUMMARY:Elranatamab: Phase 2 readout est. (NCT07789522)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Safety and Ef
 ficacy of Elranatamab Plus Isatuximab\, Bortezomib\, and Lenalidomide in U
 ltra-High-Risk Multiple Myeloma\nEstimated primary completion: 9 October 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/elranatamab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07789522
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06215118-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20271116
DTEND;VALUE=DATE:20271117
SUMMARY:Elranatamab: Phase 1 readout est. (NCT06215118)
DESCRIPTION:Elranatamab\, phase 1\, Multiple Myeloma.\nStudy: A Study to Le
 arn About the Effects of the Combination of Elranatamab (PF-06863135) and 
 Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (Magne
 tisMM-30)\nEstimated primary completion: 16 November 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/elranatamab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06215118
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06138275-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06138275)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Elranatamab i
 n R/R Multiple Myeloma\nEstimated primary completion: 1 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/elranatamab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06138275
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06920251-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06920251)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Phase II Tria
 ls of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab 
 Therapy\nEstimated primary completion: 31 December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/elranatamab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06920251
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06106945-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20280124
DTEND;VALUE=DATE:20280125
SUMMARY:Elranatamab: Phase 1/2 readout est. (NCT06106945)
DESCRIPTION:Elranatamab\, phase 1/2\, Multiple Myeloma.\nStudy: AZD0305 as 
 Monotherapy or in Combination With Anticancer Agents in Participants With 
 Multiple Myeloma\nEstimated primary completion: 24 January 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/elranatamab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06106945
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06121843-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Elranatamab: Phase 1 readout est. (NCT06121843)
DESCRIPTION:Elranatamab\, phase 1\, Multiple Myeloma.\nStudy: A Study to Ev
 aluate the Safety\, Effectiveness and Tolerable Dose of Arlocabtagene Auto
 leucel (BMS-986393) in Novel Combinations in Participants With Relapsed an
 d/or Refractory Multiple Myeloma\nEstimated primary completion: 1 August 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/elranatamab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06121843
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06799026-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Elranatamab: Phase 1 readout est. (NCT06799026)
DESCRIPTION:Elranatamab\, phase 1\, Multiple Myeloma.\nStudy: A Phase 1 Stu
 dy of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions i
 n Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma\
 nEstimated primary completion: 1 September 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/elranatamab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06799026
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931704-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06931704)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Comparison of
  Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-
 transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (E
 lMMA)\nEstimated primary completion: 30 November 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/elranatamab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06931704
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07280013-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Elranatamab: Phase 1 readout est. (NCT07280013)
DESCRIPTION:Elranatamab\, phase 1\, Multiple Myeloma.\nStudy: A Study to Le
 arn About the Effects of Cemsidomide in Combination With Elranatamab in Re
 lapsed/Refractory Multiple Myeloma Subjects\nEstimated primary completion:
  December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elran
 atamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07280013
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07382739-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Elranatamab: Phase 2 readout est. (NCT07382739)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: A Phase 2 Stu
 dy of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in
  Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (
 EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"\nEstimated primary co
 mpletion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/elranatamab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07382739
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06569147-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Elranatamab: Phase 1/2 readout est. (NCT06569147)
DESCRIPTION:Elranatamab\, phase 1/2.\nStudy: Elranatamab in Patients With R
 elapsed or Refractory AL Amyloidosis\nEstimated primary completion: 1 Janu
 ary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elranatamab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT065
 69147
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07881835-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20290216
DTEND;VALUE=DATE:20290217
SUMMARY:Elranatamab: Phase 4 readout est. (NCT07881835)
DESCRIPTION:Elranatamab\, phase 4\, Multiple Myeloma.\nStudy: A Phase IV St
 udy to Learn About the Study Medicine Called Elranatamab in People With Mu
 ltiple Myeloma That is Not Responding to Four or More Standard Treatments 
 or Has Come Back After Several Standard Treatments\nEstimated primary comp
 letion: 16 February 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/elranatamab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07881835
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06947083-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06947083)
DESCRIPTION:Elranatamab\, phase 2.\nStudy: Elranatamab Post Cilta-cel in Pa
 tients With Clinical High Risk Relapsed Myeloma\nEstimated primary complet
 ion: April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elra
 natamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06947083
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07454382-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20290827
DTEND;VALUE=DATE:20290828
SUMMARY:Elranatamab: Phase 2 readout est. (NCT07454382)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: A Study of El
 ranatamab and Cyclophosphamide in People With Multiple Myeloma\nEstimated 
 primary completion: 27 August 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/elranatamab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07454382
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07637578-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Elranatamab: Phase 2 readout est. (NCT07637578)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: A Study of El
 ranatamab Outpatient Administration in Patients With Relapsed/Refractory M
 ultiple Myeloma\nEstimated primary completion: October 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/elranatamab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07637578
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06711705-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06711705)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Elranatamab i
 n Relapsed/Refractory Multiple Myeloma\nEstimated primary completion: Dece
 mber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elranatama
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 711705
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647432-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Elranatamab: Phase 1 readout est. (NCT07647432)
DESCRIPTION:Elranatamab\, phase 1.\nStudy: HEME-25 Open-Label Feasibility S
 tudy of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmabla
 stic Lymphoma With or Without HIV\nEstimated primary completion: 1 Decembe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/elranatamab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07647
 432
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06207799-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06207799)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Pre-transplan
 t Purging and Post-transplant MRD-guided Maintenance Therapy With Elranata
 mab in Patients With High-risk Multiple Myeloma\nEstimated primary complet
 ion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/elranatamab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06207799
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06997081-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06997081)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: ERd Combinati
 on Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)\nEstimated 
 primary completion: 30 September 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/elranatamab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06997081
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05623020-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20301018
DTEND;VALUE=DATE:20301019
SUMMARY:Elranatamab: Phase 3 readout est. (NCT05623020)
DESCRIPTION:Elranatamab\, phase 3\, Multiple Myeloma.\nStudy: A Study to Le
 arn About the Effects of the Combination of Elranatamab\, Daratumumab and 
 Lenalidomide Compared With Daratumumab\, Bortezomib\, Lenalidomide\, and D
 examethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not
  Candidates for Transplant\nEstimated primary completion: 18 October 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/elranatamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05623020
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07247097-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Elranatamab: Phase 2 readout est. (NCT07247097)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: ELDORADO: Elr
 anatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnos
 ed Transplant Ineligible/Deferred Multiple Myeloma\nEstimated primary comp
 letion: 1 December 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/elranatamab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07247097
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07524634-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Elranatamab: Phase 2 readout est. (NCT07524634)
DESCRIPTION:Elranatamab\, phase 2.\nStudy: Dose Schedule Study of BCMA Bisp
 ecific Antibody\, Elranatamab\, for Newly Diagnosed Immunoglobulin Light C
 hain (AL) Amyloidosis\nEstimated primary completion: June 2031. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/elranatamab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07524634
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07901868-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Elranatamab: Phase 2 readout est. (NCT07901868)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Elranatamab W
 ith Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Mul
 tiple Myeloma\nEstimated primary completion: December 2031. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/elranatamab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07901868
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06057402-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20320222
DTEND;VALUE=DATE:20320223
SUMMARY:Elranatamab: Phase 4 readout est. (NCT06057402)
DESCRIPTION:Elranatamab\, phase 4\, Multiple Myeloma.\nStudy: Elranatamab P
 ost Trial Access Study for Participants With Multiple Myeloma (MM)\nEstima
 ted primary completion: 22 February 2032. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/elranatamab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06057402
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06483100-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06483100)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Measurable Re
 sidual Disease-Guided Post-Transplant Elranatamab Maintenance\nEstimated p
 rimary completion: 30 June 2032. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/elranatamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06483100
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06974786-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06974786)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Frontline T-c
 ell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Resid
 ual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple My
 eloma\nEstimated primary completion: November 2032. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/elranatamab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06974786
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918002-3143@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20360531
DTEND;VALUE=DATE:20360601
SUMMARY:Elranatamab: Phase 3 readout est. (NCT06918002)
DESCRIPTION:Elranatamab\, phase 3\, Multiple Myeloma.\nStudy: Elranatamab/L
 enalidomide Consolidation and/or Elranatamab Maintenance Versus Standard o
 f Care After D-VRd Induction in Transplant-eligible NDMM Patients\nEstimat
 ed primary completion: May 2036. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/elranatamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06918002
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
